HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BPN14770

a novel phosphodiesterase-4D negative allosteric modulator

Also Known As:

2-(4-((2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl)methyl)phenyl)acetic acid

Networked: 5 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - BPN14770: 5
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Acetates: 4994
      - BPN14770: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - BPN14770: 5

Experts

1.	Gurney, Mark E: 5 articles (01/2021 - 11/2017)
2.	O'Donnell, James M: 3 articles (11/2019 - 10/2018)
3.	Xu, Ying: 3 articles (11/2019 - 10/2018)
4.	Zhang, Han-Ting: 3 articles (11/2019 - 10/2018)
5.	Fox, David: 2 articles (01/2019 - 10/2018)
6.	Zhang, Chong: 2 articles (01/2019 - 10/2018)
7.	Berry-Kravis, Elizabeth M: 1 article (01/2021)
8.	Ethridge, Lauren E: 1 article (01/2021)
9.	Furman, Jeremiah: 1 article (01/2021)
10.	Harnett, Mark D: 1 article (01/2021)

Related Diseases

1.	Fragile X Syndrome (Martin Bell Syndrome) 11/07/2017 - "Thus, BPN14770 may be useful for the treatment of fragile-X syndrome and other disorders with decreased cAMP signaling." 01/01/2021 - "The goal of this study was to determine whether a phosphodiesterase-4D (PDE4D) allosteric inhibitor (BPN14770) would improve cognitive function and behavioral outcomes in patients with fragile X syndrome (FXS). " 01/01/2019 - "The lead compound, 28 (BPN14770), has entered midstage, human phase 2 clinical trials for the treatment of Fragile X Syndrome."
2.	Memory Disorders (Memory Loss) 11/01/2019 - "SIGNIFICANCE STATEMENT: This study demonstrates that a phosphodiesterase-4D allosteric inhibitor, BPN14770, protects against memory loss and neuronal atrophy induced by oligomeric Aβ 1-42. " 11/01/2019 - "The protective effects of BPN14770 against Aβ-induced memory deficits, synaptic damage, and the alteration in the cAMP-meditated cell signaling cascade were blocked by H-89 (N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride), an inhibitor of protein kinase A. "
3.	Atrophy 11/01/2019 - "SIGNIFICANCE STATEMENT: This study demonstrates that a phosphodiesterase-4D allosteric inhibitor, BPN14770, protects against memory loss and neuronal atrophy induced by oligomeric Aβ 1-42. "
4.	Vomiting 10/01/2018 - "In mice engineered to express PDE4D with this primate-specific sequence, BPN14770 was 100-fold more potent for improving memory than in wild-type mice; meanwhile, it exhibited low potency in a mouse surrogate model for emesis. "
5.	Alzheimer Disease (Alzheimer's Disease) 11/01/2019 - "These results suggest that BPN14770 may activate compensatory mechanisms that support synaptic health even with the onset of amyloid pathology in Alzheimer's disease. "

Related Drugs and Biologics

1.	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)
2.	N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)
3.	Type 4 Cyclic Nucleotide Phosphodiesterases
4.	Amyloid (Amyloid Fibrils)